Data as of mid-2026
The longevity industry is legitimate as a scientific field and simultaneously carries a consumer marketing layer that is not. As of 2026 it has FDA-cleared human trials, published clinical data and institutional capital from sovereign wealth funds and national research agencies. It also has no approved drug that targets ageing itself, and the consumer wellness market that borrows its vocabulary attracts far more money than the science does. Both things are true, and treating the sector as one thing is what produces bad answers in either direction.
The question is usually asked as though there were one answer. There isn’t, because there is no single longevity industry. There are two, they share a vocabulary, and one of them is very much larger than the other.
What is the difference between longevity science and the wellness industry?
Mo Elzek, founder of the London Longevity Network, has spent several years convening the people building the science. Asked where the hype in longevity actually sits, he does not point at the biotech.
“There is a lot of hype in wellness, because there is money — direct money. It is an insane amount of money in vitamins and nutrition pumps and all these devices. That is way, way overhyped compared to biotech. Even the most hyped biotech receives less than $100 million. It is so small compared to what the wellness industry is taking.”
Mo Elzek, founder, London Longevity Network
This is the distinction that most coverage misses. One sector is running regulated clinical trials on hypotheses that may fail. The other sells certainty at retail. They are described with the same word.
“It is totally unregulated. They can literally market whatever they want and we will call it longevity.”
Mo Elzek
What changed in longevity science in 2026
Three things happened this year that had not happened before, and they are why the scientific tier can no longer be dismissed as speculation.
- The first human trial of partial cellular reprogramming — resetting the biological age of cells — began. Life Biosciences’ ER-100 received FDA IND clearance in January 2026.
- A drug intended to extend lifespan came closer to approval than any before it. The FDA accepted Loyal’s Target Animal Safety package for LOY-002 in January 2026. The species is dogs, which matters — but the regulatory pathway is real.
- Human clinical data was published. Longeveron reported Phase 2b results in Cell Stem Cell in February 2026 showing improvement in age-related frailty.
None of these is a cure for ageing. What they establish is that the field has moved from arguing about whether ageing is treatable to running regulated trials to find out.
How many people actually work in longevity research?
The most useful corrective to the hype question is a headcount. Longevity dominates a certain kind of podcast, newsletter and supplement label. The research base underneath it is tiny.
“If you count how many people are actually doing something on ageing, it is perhaps fewer than a thousand people all over the world. Think of the millions of scientists trying to fix cancer or Alzheimer’s.”
Mo Elzek
Elzek argues this is the field’s central structural problem, and that it produces a second one — an echo chamber in which bad ideas are insufficiently challenged.
“It is a small industry, and as in every small industry, you do not hear many different voices. That is dangerous. We need the industry to be ten, a hundred times bigger.”
Mo Elzek
Read the hype question through that lens and it inverts. The problem is not that too much attention is being paid to longevity. It is that the attention and the money have landed overwhelmingly on the consumer tier, while the science that would justify any of it is being done by a group small enough to fit in a lecture theatre.
Which parts of the longevity industry are overhyped?
The sceptics are not wrong. They are usually aiming at the right target from the wrong distance.
The consumer tier sells certainty the science has not earned: supplements marketed on mechanisms demonstrated in yeast or mice, clinics stacking interventions with no way to attribute which one worked, biological age tests sold as diagnostics while the clocks they run on are still being validated. Elzek’s verdict on the supplement layer is unusually direct for someone inside the field.
“There is no amount of vitamins that will make you live longer, and there is no guarantee it will make you feel healthier. Most of it is really dangerous marketing.”
Mo Elzek
He is equally direct about what does work, and it is not for sale.
“They are very minimal compared to the fundamentals, which is hormesis — inducing a little bit of stress in your system. That comes from fasting a little, exercising a little, sleeping well. That is basically it.”
Mo Elzek
There is a commercial risk in this that the industry has not priced. Consumers who buy heavily now and feel nothing later do not conclude that they bought the wrong tier. They conclude that longevity does not work — and that verdict lands on the science as well as the supplements.
The strongest arguments against longevity science
An honest verdict has to survive the strongest objections rather than the weakest. Here are the six that matter, including two the field’s own practitioners concede.
| The objection | Verdict | The evidence |
| It is rich men buying immortality | Partly true | Bezos, Altman, Thiel, Ellison and Zuckerberg are all funders. But sovereign wealth and federal science budgets have followed: Hevolution commits up to $1bn a year, and ARPA-H’s PROSPR programme put $144m of US federal money into anti-ageing research in February 2026. |
| Nothing has actually been approved | True | No drug targeting ageing itself has human approval. The closest is LOY-002, a canine lifespan drug whose safety package the FDA accepted in January 2026. The species is dogs. |
| Reprogramming is unproven in humans | Conceded | Elzek: the only long-term evidence comes from mice that look and function younger but do not live much longer. Life Biosciences’ ER-100 received FDA IND clearance in January 2026; the trial is running now, and the readout does not exist yet. |
| Nobody knows what actually drives ageing | Conceded | Elzek: the hallmarks of ageing do not contribute equally, and there is no single universal hallmark driving the process. Most companies bet deep on one. |
| Supplement marketing dressed as biotech | Two industries | The consumer wellness tier and the clinical research tier share vocabulary and almost nothing else. Conflating them is the most common error in coverage of this sector — and the wellness tier is far larger. |
| It is a bubble | Unresolved | Altos raised $5.5bn and is five years in with no clinical readout. Calico’s eleven-year AbbVie partnership ended in November 2025. Both outcomes remain live. |
The two conceded rows are the important ones. On partial reprogramming — the field’s most funded bet — Elzek is candid about how thin the long-term evidence is.
“We have no idea what happens in the long term. The only experience we have is from mice that look and function younger, but they also do not live much longer. We have very sparse information about how that affects lifespan.”
Mo Elzek
And on the underlying model, he is blunter still: the hallmarks of ageing are not equal contributors, and nobody knows which one dominates.
“There is not one universal hallmark that drives all of it. We have no idea which one it is so far.”
Mo Elzek
He also rejects the single-shot premise that most consumer coverage assumes.
“I do not think it is going to be one treatment, one shot you take like these GLP-1 peptides, and then you are young again.”
Mo Elzek
What is holding longevity research back?
Asked what the field most needs, Elzek does not say money — pointing out that cancer and Alzheimer’s research have absorbed enormous funding without proportionate returns. He names intellectual lock-in instead.
“There is a problem when you have value locking. You have an idea, and then generations of people go in the wrong direction. We do not want to be obsessed with one way of longevity. We need to be open to being completely wrong about some things.”
Mo Elzek
That is a striking thing to hear from someone whose organisation exists to promote the field, and it is the strongest argument for taking it seriously. A sector confident enough to say it might be wrong is behaving like science. One that cannot is behaving like marketing.
So, is the longevity industry legitimate?
As a scientific field: yes, and the 2026 regulatory milestones are the evidence. As an investment category: real, concentrated and unproven at the exit stage — no major longevity biotech has yet delivered a return that validates the thesis. As a consumer market: buyer beware, and the gap between what is sold and what is demonstrated is widest here.
Some of the bets being placed will fail. The most ambitious ones almost certainly will. But the field has passed the point where it can be dismissed as Silicon Valley vanity or fringe science. Something is being built, and the people building it do not have time to wait.
Elzek’s own framing is the most useful one to end on, because it deflates the question rather than answering it.
“We just hear the word longevity in different contexts. Let’s be true to ourselves: it is medicine. You do not go to hospital and say, I feel bad today, can you give me a longevity? But that is basically what they do — they try to prevent disease from happening, diagnose you, intervene early.”
Mo Elzek
On that reading the legitimacy question dissolves into a more useful one. Not whether longevity is real, but whether a given claim is medicine with evidence behind it or a product with a word attached.
Frequently asked
Is longevity science real or a scam?
Both, in different tiers. The clinical research sector is real: FDA-cleared trials, published data and institutional capital. The consumer wellness market that borrows its vocabulary is largely unproven and, in the words of London Longevity Network founder Mo Elzek, “totally unregulated — they can literally market whatever they want and we will call it longevity.”
How many people actually work on longevity?
Fewer than a thousand worldwide are working directly on the biology of ageing, according to Mo Elzek, founder of the London Longevity Network — against millions of scientists working on cancer and Alzheimer’s. The public noise around longevity is substantially larger than the research field generating it.
Has any anti-ageing drug been approved?
No drug targeting ageing itself has been approved for humans. The closest is LOY-002, a canine lifespan extension drug from Loyal, whose Target Animal Safety package the FDA accepted in January 2026.
Do longevity supplements work?
There is no strong evidence that supplements extend lifespan. Elzek’s assessment is blunt: any effect is minimal next to the fundamentals — mild fasting, exercise and sleep — which work through hormesis and cost nothing. The supplement tier attracts far more consumer spending than longevity biotech attracts investment.
Why are billionaires investing in longevity?
Because they treat ageing as an engineering problem. Silicon Valley reads living systems as information systems — genes execute code, proteins are machines — and from that angle ageing looks like accumulated errors in a complex system rather than destiny. Complex systems can be repaired.
How much is the longevity industry worth?
The global longevity economy is estimated at $27.6bn in 2026, forecast to reach $67bn by 2035 (Deep Knowledge Group, SNS Insider). The larger prize is macroeconomic: research in Nature Aging estimates that adding ten healthy years to global life expectancy would be worth $367 trillion to the world economy.
About this analysis
Mo Elzek is the founder of the London Longevity Network, which began as a pub meetup and now convenes researchers, founders and investors working on the biology of ageing. He was interviewed by Unfiltered in 2026. Supporting figures draw on The Longevity Money Map and the Longevity 100, Unfiltered’s annual report on where longevity capital is going and the only ranked power list that charts it. Data is as of mid-2026 and is updated annually.
